A Study of Combined Therapy With Stelazine and "Parnate" (Skf 385) in Chronic Anergic Schizophrenics

Buffaloe, William J.; Sandifer, Myron G.

doi:10.1176/ajp.117.11.1030

Cited by 18 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the controlled studies, 5 were rated as “2−”, 19–23 with 2 articles being secondary analyses on safety aspects of the same study, 20,22 and 12 were rated as “3” 24–37 according to SIGN criteria. None was better rated than “2−”.…”

Section: Resultsmentioning

confidence: 99%

“…[19][20][21][22][23][24][25] Two studies were controlled studies with data on TCP + lithium combination strategies, 26,27 and 10 were controlled studies with data on TCP + antipsychotic (all fist-generation antipsychotics [FGAs]) combination strategies. [28][29][30][31][32][33][34][35][36][37] Eight articles were noncontrolled studies including data on TCP + TCA combination strategies, 16,[38][39][40][41][42][43][44] 3 were noncontrolled studies including data on TCP + lithium or another mood stabilizer, 38,45,46 13 were noncontrolled studies including data on TCP + antipsychotic (FGAs and second-generation antipsychotics [SGAs]) combination strategies, 38,[47][48][49][50][51][52][53][54][55][56][57][58] 1 study included data on TCP + benzodiazepine combination, 38 1 included data on TCP + thyroxine,…”

Section: Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

60 Years of Combining Tranylcypromine

Wagner

Seemüller

Hasan

2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Background: Tranylcypromine is the only irreversible monoamine oxidase inhibitor that is approved in the United States and in Europe for the management of treatment-resistant major depressive disorder. Comprehensive data in the literature regarding the efficacy and tolerability of tranylcypromine (TCP) combination strategies have not been systematically investigated yet. Methods:We conducted a systematic review of available literature based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Study types considered eligible for inclusion were studies that reported information on efficacy and/or tolerability/ adverse effects of pharmacological TCP add-on or coadministration strategies among people with psychiatric disorders.Results: Ninety-six articles were included in qualitative analyses. A relevant body of evidence shows that TCP combined with first-and secondgeneration antipsychotics seems relatively safe and might have beneficial effects in some patients with depressive disorders, although caution is needed with some second-generation antipsychotics that have proserotonergic activity. Although evidence is not entirely consistent, amitriptyline as add-on agent might be efficacious and associated with a low rate of severe adverse events. Although available data from case reports are scarce, certain other agents, such as trazodone, but also lithium, seem to have a good riskbenefit profile with regard to TCP that should be further investigated in the context of high-quality studies.Conclusions: Any combination of a psychotropic with TCP should be preceded by an evaluation of drug-to-drug interaction and an informed consent process and followed by close monitoring. Before any combination strategy, doctors should reevaluate factors of pseudo-treatment resistance, such as rapid-metabolizing status, noncompliance, trauma, alternative diagnosis, or drug abuse.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Included Studiesmentioning

confidence: 99%

60 Years of Combining Tranylcypromine

Wagner

Seemüller

Hasan

2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…Thus Casey et al [1961] used isocarboxazid along with chlorpromazine and concluded that this combination was not superior to chlorpromazine and a placebo. Buffaloe et al [1961] concluded that a combination of stelazine and pamate was not superior to stelazine alone. In other trials, only small numbers of patients are included and no double blind technique has been used so that placebo effect cannot be excluded.…”

Section: The Effect Of Motto-amine Oxidase Inhibitors In Schizophreniamentioning

confidence: 99%